| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/26/2009 | US20090054304 Heterocyclic modulators of tgr5 for treatment of disease |
| 02/26/2009 | US20090054303 Crystal forms of saxagliptin and processes for preparing same |
| 02/26/2009 | US20090054302 Methods and Preparations For Curing Clinically Ill Patients |
| 02/26/2009 | US20090054301 Hypoallergenic composition |
| 02/26/2009 | US20090054300 Using protein profiles aspredictive tools in prognosis and treatment of immune related disorders |
| 02/26/2009 | US20090053816 Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders |
| 02/26/2009 | US20090053791 Methods and composition for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| 02/26/2009 | US20090053763 Tumor endothelial marker 7-alpha molecules and uses thereof |
| 02/26/2009 | US20090053734 Identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex; cancer, diabetes; isolating AM-binding proteins wherein AM is conjugated with a label or marker and incubated with cellular or extracellular lysates |
| 02/26/2009 | US20090053707 Methods for lightening skin and hair |
| 02/26/2009 | US20090053339 Composition for treatment of menopause |
| 02/26/2009 | US20090053332 Compositions for diabetes treatment and prophylaxis |
| 02/26/2009 | US20090053317 Microparticulate systems for the oral administration of biologically active substances |
| 02/26/2009 | US20090053315 Thermo-Kinetic Mixing for Pharmaceutical Applications |
| 02/26/2009 | US20090053314 Submicronization of proteins using supercritical fluids |
| 02/26/2009 | US20090053311 Pharmaceutical Compositions for Treating or Preventing Bone Conditions |
| 02/26/2009 | US20090053299 Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery |
| 02/26/2009 | US20090053296 Using cell-mediated immune response to e6 and e7 peptides as diagnostic/prognostic indication of recurrence and/or development of cervical intraepithelial neoplasia (CIN) |
| 02/26/2009 | US20090053292 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof |
| 02/26/2009 | US20090053288 Hemostatic woven fabric |
| 02/26/2009 | US20090053283 such as vulvodynia via comprising administering polyarginine; for treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing agents |
| 02/26/2009 | US20090053278 Anti-microbial compositions and devices and methods of using the same |
| 02/26/2009 | US20090053263 Inhibitors of Enveloped Virus Infectivity |
| 02/26/2009 | US20090053255 Anti-arthropod vector vaccines, methods of selecting and uses thereof |
| 02/26/2009 | US20090053254 Recombinant human alpha-fetoprotein as an immunosuppressive agent |
| 02/26/2009 | US20090053253 Process for the measurement of the potency of glatiramer acetate |
| 02/26/2009 | US20090053252 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 02/26/2009 | US20090053248 Compositions and methods for transepithelial molecular transport |
| 02/26/2009 | US20090053242 Thrombopoietic compounds |
| 02/26/2009 | US20090053237 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections |
| 02/26/2009 | US20090053234 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents |
| 02/26/2009 | US20090053232 Modulation of synaptogenesis |
| 02/26/2009 | US20090053231 Optical Disc Apparatus |
| 02/26/2009 | US20090053229 Methods of Treating Conditions Involving Neuronal Degeneration |
| 02/26/2009 | US20090053226 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/26/2009 | US20090053222 Inhibitors of CD200 such as antibodies or antisense agents for treating cancer, tumor, leukemia |
| 02/26/2009 | US20090053209 Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells |
| 02/26/2009 | US20090053208 Methods and Systems for Improving Tissue Perfusion |
| 02/26/2009 | US20090053203 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, obesity, cardiovascular, metabolic, neurodegenerative, gastrointestinal, autoimmune, rheumatological and infectious diseases; drug delivery |
| 02/26/2009 | US20090053201 Using variation in DNA polymerase sequence as diagnostic indicator of adefovir or tenofovir resistance in virus; viricides |
| 02/26/2009 | US20090053200 Method for retarding unhealth manifestations brought by ageing of human beings |
| 02/26/2009 | US20090053199 Stable Dairy Components Effective for Fat Loss |
| 02/26/2009 | US20090053198 Cytokine Induction of Selectin Ligands on Cells |
| 02/26/2009 | US20090053196 Chn-1/Chip-Antagonists For The Treatment Of Muscular Diseases |
| 02/26/2009 | US20090053194 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| 02/26/2009 | US20090053193 Use of Factor VIIa for the Treatment of Burn Trauma |
| 02/26/2009 | US20090053192 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 02/26/2009 | US20090053191 Phospholipases, nucleic acids encoding them and methods for making and using them |
| 02/26/2009 | US20090053190 Biodrugs comprising polypeptides and carriers comprising bioadhesives such as fibrin, for treatment of vision defects; chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating cancer |
| 02/26/2009 | US20090053189 Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
| 02/26/2009 | US20090053188 Method of preventing reduced feed intake in animals and treatment of disease conditions |
| 02/26/2009 | US20090053186 Therapy for primary and metastatic cancers |
| 02/26/2009 | US20090053185 Coagulation factor x polypeptides with modified activation properties |
| 02/26/2009 | US20090053178 Use of herpes vectors for tumor therapy |
| 02/26/2009 | US20090053177 Protein-polymer conjugates |
| 02/26/2009 | US20090053176 New Combination 937 |
| 02/26/2009 | US20090053175 Substitute pyrrolidine derivatives |
| 02/26/2009 | US20090053174 Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
| 02/26/2009 | US20090053173 Stabilization of such as human interleukin 11; reduced toxicity; cost effective; shelf life; SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma; between a human serum albumin and an Interferon |
| 02/26/2009 | US20090053172 Heterocyclic compounds as ccr5 antagonists |
| 02/26/2009 | US20090053171 Treatment of cellular proliferative disorders |
| 02/26/2009 | US20090053170 Human prostate cell lines in cancer treatment |
| 02/26/2009 | US20090053169 Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same |
| 02/26/2009 | US20090053168 Such as multiple myeloma using an adenosine A2A receptor agonist e.g., SCH 58261, IB-MECA (CF 101), Cl-IBMECA, CGS-21680, Regadenoson, apadenoson, binodenoson, BVT-115959, and UK-432097 |
| 02/26/2009 | US20090053167 C-, S- and N-glycosylation of peptides |
| 02/26/2009 | US20090053151 Antibacterial peptides and analogues thereof |
| 02/26/2009 | US20090053149 nonionic surfactant such as Tyloxapol in a sterile aqueous solution of an antimicrobial such as an antibiotic; phosphatide-free; aerosol drug delivery to lungs |
| 02/26/2009 | US20090053147 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 02/26/2009 | US20090053136 Therapeutic immunoglobulin specific for lymphocyte adhesion protein for killing and/or inhibiting growth of cancer cells |
| 02/26/2009 | DE112007001030T5 Amyloid-ß-Fibrillogenese-inhibierendes Peptid Amyloid-beta fibrillogenesis-inhibiting peptide |
| 02/26/2009 | DE102007039429A1 Verfahren zur Aktivierung regulatorischer T-Zellen A process for the activation of regulatory T cells |
| 02/26/2009 | CA2707840A1 Amino acid substituted molecules |
| 02/26/2009 | CA2697261A1 Treatment of lung cancer |
| 02/26/2009 | CA2697252A1 Calmodulin-binding peptides that reduce cell proliferation in cancer and smooth muscle proliferation diseases |
| 02/26/2009 | CA2697036A1 Methods of treating and protecting against human immunodeficiency virus |
| 02/26/2009 | CA2696979A1 Materials and methods for treating or preventing organophosphate exposure associated damage |
| 02/26/2009 | CA2696701A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | CA2696597A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696591A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696570A1 Cyclic depsipeptides |
| 02/26/2009 | CA2696398A1 Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist |
| 02/26/2009 | CA2696208A1 Treatment with kallikrein inhibitors |
| 02/26/2009 | CA2695532A1 Polymeric linkers containing pyridyl disulfide moieties |
| 02/26/2009 | CA2695321A1 Methods for promoting stem cell proliferation and survival |
| 02/26/2009 | CA2695012A1 Treatment with kallikrein inhibitors |
| 02/26/2009 | CA2693846A1 A memory influencing protein |
| 02/26/2009 | CA2693152A1 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 02/26/2009 | CA2688215A1 The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| 02/26/2009 | CA2687028A1 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| 02/25/2009 | EP2028493A1 Procalcitonin 3-116 |
| 02/25/2009 | EP2028278A1 RNA sequence-specific mediators of RNA interference |
| 02/25/2009 | EP2028275A2 Protein glycosylation modification in pichia pastoris |
| 02/25/2009 | EP2028274A2 An antisense oligonucleotide against the TGF-beta2 gene |
| 02/25/2009 | EP2028269A1 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and uses thereof |
| 02/25/2009 | EP2028192A1 GLP-1 and methods for treating diabetes |
| 02/25/2009 | EP2028191A1 Peptides and compounds that bind to a receptor |
| 02/25/2009 | EP2028190A1 Compounds and methods for therapy and diagnosis of lung cancer |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2028186A2 Hepatitis C inhibitor tri-peptides |
| 02/25/2009 | EP2028185A1 Tubulysin and tubulysin agent |